Clinical Trial for Severely Ill COVID-19 Patients Now Underway at Montefiore-Einstein

(BRONX, NY)—April 3, 2020—Montefiore Health System andAlbert Einstein College of Medicine has started treating very sick COVID-19 patients as part of a multicenter trial evaluating a potential therapy for the new disease. The double-blind, placebo-controlled trial is testing whether sarilumab, a drug already approved for treating rheumatoid arthritis, can halt the inflammation that can overwhelm the lungs of COVID-19 patients. A very similar drug yielded promising results in a recent study involving patients in China.
Source: Einstein News - Category: Universities & Medical Training Source Type: news

Related Links:

In the largest observational study thus far investigating the drug hydroxychloroquine as a treatment for COVID-19, researchers found little evidence that it helps, and worrying evidence that the medication may cause harm. In a study published May 22 in the journal Lancet, scientists in the U.S. and Switzerland report on an analysis of more than 96,000 people hospitalized with confirmed COVID-19 in 671 hospitals on six continents. Nearly 15,000 patients were treated with one of the following: chloroquine (which is an older version of hydroxychloroquine), hydroxychloroquine, or either of those drugs in combination with an an...
Source: TIME: Science - Category: Science Authors: Tags: Uncategorized COVID-19 UnitedWeRise20Disaster Source Type: news
This study showed that a five-day regimen is as effective as 10 days–that’s important, doctors say, since it could mean shorter stays in the hospital, which could alleviate some of the burden on the health care system. “Of course we will have to wait for the final review of all the data, but it would be very nice to have an anti-viral that’s efficacious in this terrible illness,” says Dr. Aruna Subramanian, a clinical professor of medicine at Stanford and an investigator on the study. “At least we know that we can help patients with this, and that’s really the bottom line.” T...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 feature Magazine Source Type: news
In India, the drug sold under the brand name Actemra, is approved for the use in autoimmune disease such as rheumatoid arthritis and for six months treatment it costs Rs 2.5 lakh. For Covid-19 patients who are administered this drug, the cost is Rs 60,000 per dosage.
Source: The Economic Times - Category: Consumer Health News Source Type: news
In India, the drug sold under the brand name Actemra, is approved for the use in autoimmune disease such as rheumatoid arthritis and for six months treatment it costs Rs 2.5 lakh. For Covid-19 patients who are administered this drug, the cost is Rs 60,000 per dosage.
Source: The Economic Times - Category: Consumer Health News Source Type: news
Conditions:   Rheumatoid Arthritis;   COVID Intervention:   Sponsor:   University Hospital, Brest Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Rachel ChiuScholars have associated artificial intelligence ( “AI”) with many words over the years: overhyped, underdeveloped, and even science fiction. But COVID-19 demonstrates that despite the skepticism and hysteria there is a place for AI in society, even if that space is still legally undefined. Since AI inventorship is not suitably addressed in U.S . patent law, the advancement of AI presents practical and conceptual challenges for the aging patent system.AI refers to the simulation of human intelligence performed on machines that can imitate cognition and evaluate autonomously. Expertise in pattern...
Source: Cato-at-liberty - Category: American Health Authors: Source Type: blogs
Here are the facts on hydroxychloroquine, which the president has promoted to fight Covid-19 despite warnings from the F.D.A. that it can cause heart problems.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Hydroxychloroquine (Drug) Coronavirus (2019-nCoV) Azithromycin (Drug) Drugs (Pharmaceuticals) Preventive Medicine Research Hospitals Clinical Trials Rumors and Misinformation Rheumatoid Arthritis Lupus Erythematosus Food and Drug Adm Source Type: news
Condition:   Rheumatoid Arthritis Intervention:   Drug: Hydroxychloroquine Sponsor:   Assiut University Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Arthritis | China Health | Clinical Trials | COVID-19 | Rheumatoid Arthritis | Rheumatology | Study | Universities & Medical Training